# Cannabis Research: Cannabidiol’s Impact on Glucose Tolerance & Gut Microbiome in Obese Adults > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabidiol-impact-glucose-tolerance-obese-adults/ > **Published:** 2026-05-08T16:09:51-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:55:56-04:00 > **Clinical Summary:** Explore cannabidiol impact on glucose tolerance and gut microbiome in obese adults through recent clinical research findings and pilot studies. --- Table of Contents - [Clinical Takeaway](#Clinical_Takeaway) - [#6 Short-Term Low Dose Cannabidiol Does Not Influence Glucose Tolerance or the Gut Microbiome in Sedentary Adults with Overweight and Obesity: Pilot Study.](#6_Short-Term_Low_Dose_Cannabidiol_Does_Not_Influence_Glucose_Tolerance_or_the_Gut_Microbiome_in_Sedentary_Adults_with_Overweight_and_Obesity_Pilot_Study) - [What This Study Teaches Us](#What_This_Study_Teaches_Us) - [Why This Matters Clinically](#Why_This_Matters_Clinically) - [Study Snapshot](#Study_Snapshot) - [Where This Paper Deserves Skepticism](#Where_This_Paper_Deserves_Skepticism) - [Dr. Caplan’s Take](#Dr_Caplan8217s_Take) - [Clinical Bottom Line](#Clinical_Bottom_Line) - [Related](#Related) #### Clinical Takeaway In this pilot study, short-term low-dose CBD supplementation did not significantly improve glucose tolerance, alter gut microbiome composition, or reduce inflammation in sedentary adults with overweight or obesity. While animal studies have suggested CBD may offer metabolic benefits, these findings indicate that translating those effects to humans may require different doses, longer treatment durations, or different patient populations. This study highlights the need for larger, more rigorously designed [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) before CBD can be recommended for metabolic health management. ### #6 Short-Term Low Dose Cannabidiol Does Not Influence Glucose Tolerance or the Gut Microbiome in Sedentary Adults with Overweight and Obesity: Pilot Study. **Citation:** Ewell Taylor R et al. *Short-Term Low Dose Cannabidiol Does Not Influence Glucose Tolerance or the Gut Microbiome in Sedentary Adults with Overweight and Obesity: Pilot Study.* Cannabis and [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/). 2026. PMID: 41167732. **Study type:** Journal Article, Randomized Controlled Trial  |  **Topic area:** Cannabidiol  |  **CED Score:** 12 Design: 5 Journal: 1 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0 **Abstract:** INTRODUCTION: Epidemiological data indicate that regular users of cannabis products may be protected from type 2 diabetes, although the mechanism is not understood. Observations from animal studies suggest that the cannabinoid, cannabidiol (CBD) may protect/improve glucose tolerance; an effect that may be partially mediated by favorable modifications to the gut microbiome. The aims of the current pilot project were to gain initial insight into the influence of short-term CBD ingestion on oral glucose tolerance, the gut microbiome, and inflammation in sedentary adults with overweight or obesity and free from diabetes. MATERIALS AND METHODS: Using a randomized, double-blind, repeated measures, parallel design, oral glucose tolerance was determined in 16 adults (6 males, 10 females) prior to and following 4 weeks of daily ingestion of either placebo or CBD (30 mg every 12 h). Fecal samples were collected at baseline and post-intervention. RESULTS: Compared with placebo, CBD did not influence glucose tolerance (Matsuda Index: placebo-pre 7.6 [5.5], placebo-post 10.1 [5.5], vs. CBD-pre 11.7 [7.9], and hCBD-post 10.1 [10.2]; median [interquartile range]; p > 0.05). Characteristics of the gut microbiome or inflammation were not appreciably modified by CBD or placebo. DISCUSSION: Short-term daily ingestion of low-dose CBD did not appear to favorably modify glucose tolerance in sedentary adults with overweight or obesity. It is possible that CBD may not account for the previously reported protection from type 2 diabetes bestowed to regular users of cannabis products. ### What This Study Teaches Us Low-dose CBD (60 mg/day) for 4 weeks did not improve glucose tolerance or alter the gut microbiome in overweight sedentary adults without diabetes. This challenges the animal data suggesting CBD might protect against type 2 diabetes through microbiome changes. ### Why This Matters Clinically Cannabis users show epidemiological protection from type 2 diabetes, but we don’t know why. If CBD were the active mechanism, it would be a tractable treatment target. This negative result suggests either the effect comes from other cannabis constituents, requires higher doses or longer exposure, or depends on populations or lifestyles not captured in this trial. ### Study Snapshot **Study Design**Randomized double-blind parallel design with repeated measures**Population**16 adults (6 male, 10 female), sedentary, overweight or obese, diabetes-free**Intervention**CBD 30 mg twice daily (60 mg/day total) for 4 weeks versus placebo**Primary Outcome**Oral glucose tolerance measured by Matsuda Index, plus gut microbiome composition and inflammatory markers**Key Result**No significant difference between CBD and placebo groups on glucose tolerance (Matsuda Index p > 0.05), microbiome characteristics, or inflammation ### Where This Paper Deserves Skepticism The sample is very small (N=16) with a 2:1 female predominance, which may not generalize. The 4-week duration is short for microbiome shifts or metabolic adaptations. The dose (60 mg/day) is at the lower end of what’s commonly used in clinical practice. The abstract provides no information on baseline characteristics, allocation concealment, or whether the study was adequately powered as a pilot. These limitations make it difficult to know whether null findings reflect true absence of effect or inadequate study design to detect it. ### Dr. Caplan’s Take I read this as an important negative result that tempers expectations about CBD as a diabetes preventive. The animal data was promising, but this human trial found nothing at this dose and duration. That said, I wouldn’t extrapolate too far from a 16-person, 4-week pilot. We need larger, longer studies with higher doses and ideally in populations at higher baseline risk. The epidemiological protection in regular cannabis users remains real and unexplained. CBD may not be the answer, but I’m not ready to close the book on the mechanism yet. ### Clinical Bottom Line Low-dose CBD for 4 weeks did not improve glucose tolerance or microbiome markers in this small pilot. Don’t use CBD as a diabetes prevention strategy based on current evidence, and recognize that the protective effect seen in cannabis users likely comes from something else.  |  [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/41167732/)[DOI ↗](https://doi.org/10.1177/25785125251391085) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20Research%3A%20Cannabidiol%27s%20Impact%20on%20Glucose%20Tolerance%20%26%20Gut%20Microbiome%20in%20Obese%20Adults%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D50814)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D50814)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20Research%3A%20Cannabidiol%27s%20Impact%20on%20Glucose%20Tolerance%20%26%20Gut%20Microbiome%20in%20Obese%20Adults%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D50814)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabidiol & Glucose Tolerance: Clinical Trial Evidence](https://cedclinic.com/cannabidiol-glucose-metabolism-study-clinical-insights/) Review clinical trial evidence on cannabidiol's effects on glucose tolerance and metabolic health. [Read Clinical Trial Evidence](https://cedclinic.com/cannabidiol-glucose-metabolism-study-clinical-insights/) [Cannabidiol Glucose Tolerance Effects in Obesity](https://cedclinic.com/cannabidiol-glucose-metabolism-obesity-effects-study/) Explore research findings on cannabidiol's influence on glucose tolerance in obese populations. [Explore Research Findings](https://cedclinic.com/cannabidiol-glucose-metabolism-obesity-effects-study/) [Clinical Trial Findings on Short-Term Low-Dose Cannabidiol and Glucose Tolerance](https://cedclinic.com/short-term-low-dose-cannabidiol-glucose-tolerance-study/) Discover [clinical trial results](https://cedclinic.com/cannabidiol-liver-enzyme-elevation-healthy-adults/) evaluating short-term low-dose cannabidiol effects on glucose tolerance. [View Clinical Trial Results](https://cedclinic.com/short-term-low-dose-cannabidiol-glucose-tolerance-study/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).